Abstract
Rifampin is a potent antibiotic against staphylococcal implant-associated infections. In the absence of implants, current data suggest against the use of rifampin combinations. In the past decades, abundant preclinical and clinical evidence has accumulated supporting its role in biofilm-related infections.In the present article, experimental data from animal models of foreign-body infections and clinical trials are reviewed. The risk for emergence of rifampin resistance and multiple drug interactions are emphasized. A recent randomized controlled trial (RCT) showing no beneficial effect of rifampin in patients with acute staphylococcal periprosthetic joint infection treated with prosthesis retention is critically reviewed and data interpreted. Given the existing strong evidence demonstrating the benefit of rifampin, the conduction of an adequately powered RCT with appropriate definitions and interventions would probably not comply with ethical standards.
Highlights
Rifampin is one of the first-line drugs against tuberculosis
Most of them were treated with a rifampin combination regimen, suggesting a benefit of antibiofilm activity compared to treatment without rifampin
In 2020, a second randomized controlled trial (RCT) in patients with periprosthetic joint infection (PJI) was published, using different combination therapy regimens, which did not show a better outcome with addition of rifampin to standard treatment [8]
Summary
Rifampin is one of the first-line drugs against tuberculosis. In addition, it has been used against non-mycobacterial microorganisms, mainly staphylococci, for at least 50 years [1]. In 2020, a second RCT in patients with periprosthetic joint infection (PJI) was published, using different combination therapy regimens, which did not show a better outcome with addition of rifampin to standard treatment [8] These unexpected data may unsettle clinicians with limited experience in the field of implant-associated infections. Based on our observation that rifampin could prevent, and cure experimental staphylococcal implant-associated infections [15], we performed additional animal experiments with rifampin combination therapy [16], followed by observational studies and one randomized controlled trial in patients with orthopedic implant-associated infections [7,17,18,19]. Data from randomized controlled trials are still not available in patients with non-orthopedic implant-associated infections
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
